To report complications of cosmetic artificial iris implantation and explantation outcomes. Retrospective case series. Medical records of 12 patients (24 eyes) who presented to us after being implanted with cosmetic artificial irises elsewhere were reviewed. Data collected included baseline demographics, presenting symptoms, examination findings, and management outcomes. Eight eyes had NewColorIris implants and 16 had BrightOcular implants. The mean interval from cosmetic iris implantation to presentation was 61.7 ± 60.0 months. The mean follow-up after explantation was 35.5 ± 38.1 months. Complications at presentation included iris abnormalities (11 eyes, 45.8%), elevated intraocular pressure (8 eyes, 33.3%), corneal edema (6 eyes, 25%), intraocular inflammation (5 eyes, 20.8%), and cataract (4 eyes, 16.7%). Surgical interventions included cosmetic iris removal (19 eyes, 79.2%), cataract extraction (7 eyes, 29.2%), corneal transplantation (7 eyes, 29.2%), and glaucoma surgery (4 eyes, 16.7%). https://www.selleckchem.com/products/brigimadlin.html Complications at the last follow-up examination included native iris defects (11 eyes, 45.8%), persistent glaucoma (7 eyes, 29.2%), cataract (5 eyes, 20.8%), corneal edema (4 eyes, 16.7%), and intraocular inflammation (2 eyes, 8.3%). The mean logarithm of the minimum angle of resolution was 0.56 ± 0.47 at presentation and 0.78 ± 0.88 at the last examination (P=.30). The mean intraocular pressure was 22.7 ± 15.8 mm Hg at presentation and 13.4 ± 6.99 mm Hg at the last examination (P=.02). Cosmetic iris implantation was associated with serious complications at the time of presentation, and adverse sequelae persisted for years after explantation. Cosmetic iris implantation was associated with serious complications at the time of presentation, and adverse sequelae persisted for years after explantation. To evaluate glaucoma risk factors and associated outcomes of the Boston keratoprosthesis type I (KPro). Clinical case-control study. This is a single-center study of 140 eyes of 118 patients who underwent KPro surgery between October 2008 and March 2017 by a single surgeon. A total of 118 eyes of 118 patients with at least 6 months of follow-up were analyzed to account for intereye correlation. Patients without glaucoma were compared to those diagnosed with glaucoma, which included treatment with intraocular pressure (IOP)-lowering medications or glaucoma surgery. A subgroup analysis compared eyes with pre-KPro glaucoma with those with post-KPro glaucoma. Statistical analysis was performed using univariate and multivariate analyses and Kaplan-Meier survival curves. Main outcome measures were glaucoma diagnosis and progression. Other outcomes included demographics, preoperative diagnosis, best-corrected visual acuity, IOP, cup-to-disc ratio progression and postoperative complications. The mean age at ss without glaucoma remain at high risk of complications that can hinder promising visual outcomes. Despite all available treatments and surgical interventions, a majority of eyes will suffer from glaucoma progression, even later during follow-up. To evaluate repeat Descemet membrane endothelial keratoplasty (re-DMEK) success rates and to identify risk factors for re-DMEK failure. Retrospective case series. Settings Institutional. A chart review was performed, including all eyes with primary DMEK failure that underwent re-DMEK between 2013 and 2019 at the Toronto Western Hospital and the Kensington Eye Institute (Toronto, Ontario, Canada) and had at least 6 months of follow-up. Predicting factors for re-DMEK outcome. Of 590 consecutive DMEK surgeries, 40 eyes (6.7%) were identified for having a secondary DMEK surgery after primary DMEK failure. Etiologies for primary DMEK were Fuchs endothelial corneal dystrophy (32.5%), pseudophakic bullous keratopathy (35%), previous failed graft (27.5%), and other indications (5%). Fifty-five percent of the cohort were categorized as having a complicated anterior segment including 11 eyes with previous glaucoma surgery, 7 eyes post-penetrating keratoplasty, 4 eyes post-Descemet stripping automated endothelial keratoplasty, 3 eyes peripheral anterior synechia, 3 eyes previous pars plana vitrectomy, 2 eyes aphakia, and 1 eye each with aniridia, anterior chamber intraocular lens, and iris-fixated intraocular lens. Re-DMEK failure was documented in 12 eyes (30%) of the entire cohort. The risk factor for re-DMEK failure was the presence of a complicated anterior segment (P=.01, odds ratio=17.0 [95% confidence interval 1.92-150.85]), with 50% re-DMEK failure rate in this subgroup. Re-DMEK is a viable option for cases of primary DMEK failure, especially for eyes with Fuchs endothelial corneal dystrophy as the indication for primary DMEK without other ocular morbidities; however, eyes categorized with a complicated anterior segment had high re-DMEK failure rates.</ABSTRACT>. . We first estimated the prevalence of physical frailty in older subjects from the population-based Salus in Apulia Study (Apulia, Southern Italy), and its impact on all-cause mortality. Second, we explored the relationship between multimorbidity and physical frailty. Cross-sectional and longitudinal analyses from a population-based study. We analyzed data from the Salus in Apulia study, a population-based sample of 1929 subjects aged 65 years and older. These older participants underwent clinical, physical, and laboratory assessments. Physical frailty was operationalized using slightly modified Fried criteria. Multimorbidity status was defined as the co-presence of 2 or more chronic conditions. The overall prevalence of physical frailty in this older population from Southern Italy was 14.8% [95% confidence interval (CI) 13.26-16.49]. Physical frailty subjects were significantly older (P < .01), had a lower educational level (P<.01), increased executive dysfunction (P<.01), higher serum levels interleukin-6 (P < .01), and white blood cells (P= .01). Multimorbidity status (P<.01), diabetes mellitus (P=.05), peripheral age-related hearing loss (P < .01), cognitive impairment (P<.01), chronic obstructive pulmonary disease (P=.02), and metabolic syndrome (P=.02) were also directly related to physical frailty. Apathy increased according to the severity of physical frailty status (P=.02). There was a significantincreased risk of all-cause mortality for physical frailty subjects (hazard ratio 1.48; 95% CI 1.03-2.12, adjusted for age and sex) during the observation from the date of enrollment to the date of death (mean±SD 55.70±22.19months, median 54months). Frailty is the consequence of the contributory action of the aging process and some chronic diseases that hasten some of the changes concurrent with aging. Frailty is the consequence of the contributory action of the aging process and some chronic diseases that hasten some of the changes concurrent with aging.